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Abstract
As the catalog of oncogenic driver mutations is expanding, it becomes clear that alterations in a given gene might have
different functions and should not be lumped into one class. The transcription factor GATA3 is a paradigm of this. We
investigated the functions of the most common GATA3 mutation (X308_Splice) and five additional mutations, which
converge into a neoprotein that we called “neoGATA3,” associated with excellent prognosis in patients. Analysis of
available molecular data from >3000 breast cancer patients revealed a dysregulation of the ER-dependent transcriptional
response in tumors carrying neoGATA3-generating mutations. Mechanistic studies in vitro showed that neoGATA3
interferes with the transcriptional programs controlled by estrogen and progesterone receptors, without fully abrogating
them. ChIP-Seq analysis indicated that ER binding is reduced in neoGATA3-expressing cells, especially at distal regions,
suggesting that neoGATA3 interferes with the fine tuning of ER-dependent gene expression. This has opposite outputs in
distinct hormonal context, having pro- or anti-proliferative effects, depending on the estrogen/progesterone ratio. Our data
call for functional analyses of putative cancer drivers to guide clinical application.
Introduction
Genomics studies have produced an expanding catalog of
cancer-driving somatic mutations, which needs to be
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translated into biological and clinically applicable knowl-
edge [1]. One limitation of many studies is the tendency to
lump all mutations occurring in one gene into a single class,
which can lead to inconclusive results when stratifying
patients in a binary fashion, as different genetic alterations
might have distinct effects [2–4]. The GATA3 transcription
factor is emerging as a paradigm of a gene where multiple
classes of mutations occur, having distinct biological and
clinical output [5–8]. This is specific for breast cancer (BC),
where GATA3 is mutated in around 11% of cases and shows
a characteristic mutational pattern, different from other
tumor types [2, 3].
Several evidences implicate GATA3 in the activation of
the mammary differentiation program: (1) in normal tissue,
it is necessary for the luminal compartment formation [9];
(2) GATA3 expression in BC strongly correlates with
estrogen receptor (ER) expression [10]; (3) GATA3 func-
tions in a complex with FOXA1 and ER to enhance tran-
scription of ER-responsive genes [11]; and (4) ectopic
expression in GATA3-negative basal-like BC cells is suf-
ficient to induce luminal differentiation and inhibit tumor
dissemination [12]. Consistently, GATA3 expression
decreases during progression to metastatic BC [13]. The
high frequency of GATA3 mutations in BC suggests that
they are driver mutations, but whether they result in loss-of-
function (LOF) or gain-of-function (GOF) is not clear. Most
GATA3 mutations are rare or unique frameshift indels
(insertion/deletions) distributed along the 3′ gene end
(Fig. 1a), consistent with the classical mutational pattern of
a tumor suppressor and therefore suggesting a LOF [2].
However, they are typically heterozygous and the expres-
sion of the wild type (WT) allele is retained [14]. A few
mutations concentrate in two clusters in exon 5 and 6,
including some “hotspots” or “warmspots,” suggesting that
they might generate GOF, instead. Whether GATA3 muta-
tions are true oncogenic drivers is also an open question:
while some in vitro and in vivo data suggest a tumor-
promoting function [6, 8, 15], in general they are associated
with longer survival [2] and better response to endocrine
therapy [16]. A recent study identified four classes of
GATA3 frameshift mutations: (1) ZnFn2 mutations, occur-
ring within the C-terminal Zn finger; (2) splice mutations,
occurring mainly between intron 4 and exon 5; (3) trun-
cating mutations, occurring downstream of the C-terminal
Zn finger; and (4) extension mutations, occurring in exon 6
and disrupting the stop codon [6]. ZnFn2 mutations produce
a highly stable truncated protein lacking the C-terminal Zn
finger, showing low affinity for DNA and altered tran-
scriptional activity, and are associated with poor outcome
when compared with other GATA3 mutations [6, 17].
Extension mutations produce a longer protein modulating
drug sensitivity [5]. The effect of splice and truncating
mutations remains unknown.
Here, we investigated the effects of the most prevalent
GATA3 hotspot somatic mutation (X308_Splice). This
mutation, like five additional ones producing partially or fully
identical C-terminal peptides, correlates with better outcome
in patients and is associated with a specific gene expression
signature, characterized by altered ER-dependent transcrip-
tional program. Combined analysis of patient-derived data
and in vitro experiments with BC cell lines shows that the
mutant protein—which we designate as “neoGATA3”—
interferes with the function of both ER and PR, blunting,
without abrogating, their downstream programs. This has
distinct biological outputs depending on the hormonal con-
text: neoGATA3-expressing cells have a proliferative
advantage when both estrogen and progesterone levels are
high while they display a growth disadvantage when estrogen
prevails. Our data suggest the existence of stage-dependent
oncogenic effects of GATA3 driver mutations.
Results
The GATA3 X308_splice mutation produces a unique
neopeptide
The most common GATA3 mutation is a 2nt deletion in
intron 4 disrupting the 3′ splice site (X308_Splice, Fig. 1a).
The predicted effect is a transcript lacking 7 nucleotides
[7, 14] which we successfully identified in RNA-Seq data
from 15/19 TCGA-BRCA samples carrying the
X308_Splice mutation but not in 20/20 tumors with either
WT GATA3 or other GATA3 mutations (Fisher’s exact
probability test P= 1.54e−07, Fig. 1b). The mutant tran-
script was validated by RT-qPCR in 4/4 independent
luminal A/B tumors carrying the X308_Splice mutation and
in 0/7 without it (Supplementary Fig. 1a). The loss of 7nt
causes a frameshift, leading to a GATA3 protein—desig-
nated neoGATA3—lacking residues 308–444, encompass-
ing the second ZnFn, and containing instead a novel 44aa
C-terminal sequence without homology to any other human
protein sequence (Fig. 1c). We raised a polyclonal anti-
serum against the novel 44aa peptide, which specifically
recognized a shorter GATA3 protein of the expected size
(37 kDa) exclusively in a tumor carrying the mutation and
in cells transduced with the mutant cDNA (Fig. 1c and
Supplementary Fig. 1b). These antibodies allowed the
detection of neoGATA3 in a tissue microarray containing
100 luminal A/B tumors with information about GATA3
mutational status with high sensitivity (90%) and specificity
(94%) (Fig. 1d).
Importantly, we identified five additional mutations,
detected in six METABRIC and one TCGA-BRCA sam-
ples, producing fully or partially identical C-terminal pep-
tides. One of them is a 2nt insertion at codon Q321, found
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after re-sequencing one METABRIC sample originally
genotyped as GATA3-WT (MB-0114) showing immunor-
eactivity with the mutant-specific antibodies (Supplemen-
tary Fig. 1c). In all, at least six different mutations, found in
78/2369 (3.3%) METABRIC samples and in 22/988 (2.2%)
TCGA-BRCA samples, produce a neoGATA3-like peptide
(Supplementary Table 1).
Patients with neoGATA3-mutant tumors display
excellent prognosis
To understand the clinical significance of neoGATA3
mutations, we analyzed the METABRIC cohort, where
clinical data are available for 1673 patients, including 231
(13.8%) with GATA3-mutant tumors. Among the latter, 66
(28.6%) had neoGATA3-type mutations and 165 (71.4%)
had other mutations. NeoGATA3 mutations were sig-
nificantly associated with lower tumor stage, grade, and size
and with expression of progesterone receptor (PR) (Sup-
plementary Fig. 2a–d), all factors predicting better outcome.
Consistently, patients with neoGATA3-mutant tumors had
significantly better overall survival (OS) compared to both
patients with WT GATA3 (HR= 0.35; 95% CI 0.23–0.53;
P < 0.001) and those carrying any other GATA3 mutation
(OtherMut) (HR= 0.48; 95% CI 0.30–0.77; P= 0.002,
Fig. 1e, left).
Importantly, neoGATA3 mutations were exclusive for
patients with ER+ tumors (Supplementary Fig. 3a), which
have better outcome [3, 18]. Even within this good-
prognosis group, the presence of neoGATA3 mutations
was strongly associated with significantly longer OS (neo-
GATA3 vs WT HR= 0.33; 95% CI 0.22–0.51; P < 0.001
and neoGATA3 vs OtherMut HR= 0.45; 95% CI
0.28–0.72; P= 0.001, Fig. 1e, right). A tendency toward
longer disease-free survival (DFS) was observed for patients
with neoGATA3-mutant tumors in the TCGA-BRCA
Fig. 1 A hotspot splice-disrupting GATA3 mutation correlates with
good outcome in breast cancer. a Distribution of the GATA3 muta-
tions in the METABRIC, TCGA-BRCA, and MSK-IMPACT cohorts
(only BC patients are shown for the latter). The two GATA boxes
indicate the two Zn finger DNA-binding domains of the GATA3
protein. b Scheme of the mutant transcript identified in tumors car-
rying the X308_Splice mutation, compared with tumors with wt
GATA3 or with any other GATA3 mutation. c Top: schematic repre-
sentation of wt GATA3, compared with the predicted neoGATA3
protein. Bottom: western blot showing the expression of wild type
GATA3 (wtG3) and the mutant neoGATA3. Black arrows indicate the
proteins of the expected size. d Representative IHC images using
either the N-ter GATA3 antibody—recognizing both wt and mutant
GATA3 (left)—or the neoGATA3-specific antibody (right) on tumors
carrying wild type GATA3 (top), or the X308_Splice mutation (bot-
tom). e Kaplan–Meier survival curves of the METABRIC patients
stratified according to GATA3 status (WT=wild type, neoGATA3=
all mutations producing a neoGATA3-like peptide, OtherMut= all
other mutations in GATA3). Left: all patients, right: ER+ patients.
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ER+ cohort although the differences were not statistically
significant, likely due to smaller sample size (Supplemen-
tary Fig. 3b). Univariate and multivariate analyses showed
that neoGATA3 is an independent prognostic factor of
longer OS and disease-specific survival (DSS) in the
METABRIC cohort (OS: HR= 0.58; 95% CI 0.36–0.92; P
= 0.02; DSS: HR= 0.46; 95% CI 0.23–0.94; P= 0.03;
Supplementary Tables 2 and 3). Consistently, none of the
1324 patients with metastatic BC included in the MSK-
IMPACT cohort harbored neoGATA3 mutations [19]
indicating that tumors with these mutations only metastasize
exceptionally (P < 0.0001, Fig. 1a).
Strikingly, approximately one-third of the neoGATA3
mutations occurred in METABRIC ER+ patients below 50
years (Supplementary Fig. 3c, P= 0.0004), suggesting that
the effect of the neoGATA3 mutations might be affected by
age or age-related factors, including the hormonal context.
To get insight into the molecular features of tumors
harboring neoGATA3 mutations, we derived a gene
expression signature based on a training set of 981 TCGA-
BRCA samples (19 neoGATA3 mutations). This signature
could identify neoGATA3-mutant tumors from the
METABRIC series (n= 2001 samples with expression and
mutation data, 63 neoGATA3) with a sensitivity of 68.3%
and specificity of 80.5% both when applied as a continuous
variable and as binary classifier. When the signature was
used to classify the samples from a cohort of patients with
no available mutational data [20], patients with tumors
classified as positive for the neoGATA3-signature (either as
continuous or binary classifier) showed significantly longer
DFS (LogRank P= 0.004, not shown).
Tumors with neoGATA3 mutations show changes in
the immune microenvironment, not consistent with
a T-cell mediated immune response
A recent study identified the neopeptide of neoGATA3 as a
potential neoantigen and suggested that it might induce an
antitumor T-cell-dependent immune response and the activa-
tion of immune checkpoints [21]. To verify this hypothesis,
we checked the expression of a set of markers of T-cell
response in the METABRIC samples. Since neoGATA3
mutations are exclusive for ER+ tumors, we only included
these tumors in all our analyses. The expression of the
T-cell marker CD8B (Mann–Whitney U test P= 0.001), and
of the immune checkpoint protein PD-L1 (P= 0.033) was
lower in neoGATA3 compared with WT tumors, while no
significant difference was observed for CD8A and PD1 (Fig.
2a). To have a broader view of the immune landscape of
neoGATA3 tumors, we used MCP counter to deconvolute the
expression of immune markers and estimate the abundance of
different cell populations [22]. A significant decrease in
“CD8+ T cell” (P= 0.0003), “NK cell” (P= 0.01), and
“Cytotoxic lymphocyte” (P= 0.021) signatures was observed
in the neoGATA3 tumors when compared with the WT
tumors while the “T cell” signature was unchanged (Fig. 2b).
We then analyzed the amount of CD8+T cells in a set of
FFPE sections from WT (n= 6) and neoGATA3 (n= 9)
tumors by IHC for CD8α protein. In accordance to gene
expression data, CD8+ cells were significantly less abundant
in neoGATA3 tumors (Fig. 2c, P= 0.048). No significant
differences at the single gene level were observed in the
neoGATA3 tumors of the TCGA cohort (Supplementary Fig.
4a) but the “C4-lymphocyte depleted” immunoscore [23] was
overrepresented among the neoGATA3 tumors (4/17 neo-
GATA3 versus 47/525 WT), although statistical significance
was not reached (P= 0.06, not shown).
In addition, the neutrophil marker ELANE (P= 0.011)
was significantly increased, whereas the M2-macrophage
markers CD163 (P= 0.0002) and MSR1 (coding for
CD204, P= 0.003) were decreased in the neoGATA3
METABRIC tumors compared with WT (Fig. 2a) and
showed similar tendencies in the TCGA-BRCA samples
(Supplementary Fig. 4b). For some of the indicated mar-
kers, a significant difference was also observed when
comparing neoGATA3 with OtherMut tumors (Fig. 2a, b).
Although the differences between neoGATA3 and Other-
Mut tumors were rather small compared to the WT tumors,
these observations suggest that the different mutations
associate with distinct immune signatures. Consistent with
these data, the MCP counter analyses revealed that the
“Neutrophil” signature was upregulated (P= 0.04) and the
“Monocytic lineage” signature was downregulated
(P= 0.001) in the neoGATA3 tumors compared with WT,
suggesting a complex modulation of the immune landscape
in tumors carrying neoGATA3 mutations (Fig. 2b).
Tumors with neoGATA3 mutations show decreased
cell cycle progression and altered ER- and PR-
dependent programs
Gene set enrichment analysis (GSEA) of the genes differen-
tially expressed in the neoGATA3 tumors compared with all
other tumors, revealed a strong downregulation of cell cycle-
and inflammation-related Hallmarks gene sets (Fig. 3a).
Accordingly, mRNA levels of E2F2 and E2F4, several
cyclins, PCNA, and MKI67 were lower in the neoGATA3
METABRIC tumors (Fig. 3b) consistent with the better
prognosis observed in patients. Similar differences were
observed at the protein level in the TCGA series with reverse-
phase protein arrays (RPPA) (Fig. 3c). This was not observed
in tumors with other GATA3 mutations (Fig. 3b, c).
Among the genes upregulated in neoGATA3 tumors, we
identified a significant enrichment of gene sets relative to
estrogen response (both early and late), WNT/β-catenin sig-
naling, and apical junctions (Fig. 3a). Interestingly, the
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neoGATA3-associated transcriptome showed positive corre-
lation with a published gene signature of good prognosis after
endocrine therapy and negative correlation with a signature of
bad prognosis in BC patients [24] (Fig. 3d).
Recent work showed that the ZnFn2 GATA3 mutations
interfere with the expression of the PGR gene, coding for
PR [6], while we observed that neoGATA3 mutations were
associated with PR expression in tumors. We then examined
several progesterone-related gene signatures and observed a
downregulation in neoGATA3 tumors (Supplementary Fig.
5a) even when restricting the analysis to premenopausal
patients, having higher progestogens levels (Fig. 3e).
Interestingly, PGR was higher in neoGATA3 pre-
menopausal tumors, compared to both WT (P= 0.01) and
OtherMut (P= 0.005) (Supplementary Fig. 5b).
The neoGATA3 protein is more stable and shows
altered DNA binding
To investigate the molecular mechanisms underlying the
association of neoGATA3 mutations with good prognosis,
we searched for cellular models carrying the X308_Splice
mutation. None of the analyzed 36 BC cell lines, which
included 10 ER+ lines, harbored this mutation, suggest-
ing that cells with neoGATA3 mutations do not grow well
in vitro. A collection of 90 PDX established from 81
patients was available [25]. While four of them carried a
GATA3 mutation, it was never neoGATA3, indicating that
tumors carrying these mutations are not efficiently
established in mice. We then attempted to introduce the
mutation in the endogenous locus of luminal BC cell
lines, but failed to identify any successfully engineered
clone among the 50 analyzed. Another report mentioned
the difficulty of generating knock-in clones with a dif-
ferent GATA3 mutation [5] supporting a general lower
fitness of GATA3-mutant BC cells in vitro. We therefore
relied on lentiviral-based transduction of BC cells with
HA-tagged neoGATA3 cDNA (HA-neoG3) and used
Flag-tagged WT GATA3 cDNA (Flag-wtG3) or an
empty vector as controls, to account for the effect of
increased GATA3 protein dosage following neoGATA3
overexpression.
Fig. 2 NeoGATA3-mutant tumors do not display a prominent
immune response. a Gene expression levels in tumors of the
METABRIC ER+ cohort, divided in the three groups according to
GATA3 status (WT n= 1189, neoGATA3 n= 66, OtherMut n= 155).
b MCP counter scores for the indicated immune cell populations in the
three groups of METABRIC ER+ tumors (WT n= 1205, neoGATA3
n= 65, OtherMut n= 161). c Representative IHC images of CD8α-
positive cells in one tumor with wt GATA3 and in one with neo-
GATA3. Quantification of the staining of WT (n= 6) and neoGATA3
(n= 9) tumors is shown under the microphotographs. Mann–Whitney
U test was used in (a, b), two-sided Student’s t test was used in (c)
*P < 0.05, **P < 0.01.
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Expression of HA-neoG3 or Flag-wtG3 in GATA3-
negative BT20 (Fig. 1c) and MDA-MB-468 cells (Supple-
mentary Fig. 6a), followed by cycloheximide treatment,
revealed that neoGATA3 is markedly more stable than the
WT protein (estimated half-life >16 h vs. 2 h, respectively)
(Fig. 4a and Supplementary Fig. 6b). Importantly, this was
not dependent on the tags, since we observed a similar
effect with untagged proteins (Supplementary Fig. 6b).
GATA3 stability is regulated by the proteasome through
progesterone-induced phosphorylation of the S308 residue,
missing in neoGATA3 [26]. Accordingly, treatment with
the proteasome inhibitor MG132 increased the half-life of
wtGATA3 but not of neoGATA3 (Supplementary Fig. 6c).
Consistent with the IHC findings in tumors (Fig. 1d) neo-
GATA3 properly localized to the nucleus even in the
absence of endogenous GATA3 (Fig. 4b and Supplemen-
tary Fig. 6d, e). However, unlike wtGATA3, purified neo-
GATA3—which lacks the C-terminal Zn finger essential for
DNA binding—showed only a weak binding to an oligo-
nucleotide containing two palindromic GATAA motifs in
an EMSA assay (Fig. 4c and Supplementary Fig. 6f).
Accordingly, neoGATA3 was unable to modulate the pro-
moter activity of CDH1 and CDH3, two known GATA3
targets [27, 28], in HEK293 cells using luciferase promoter
reporter assays (Fig. 4d). Stable wtGATA3 expression in
BT20 cells inhibited proliferation (P= 0.054) and BrdU
incorporation (P= 0.012) (Fig. 4e) while neoGATA3
expression did not (Fig. 4e). Similar results were obtained
in MDA-MB-468 cells (Supplementary Fig. 6g).
NeoGATA3 interferes with the response to estradiol
in ER+ breast cancer cells
Because neoGATA3 mutations are exclusively found in ER
+ tumors (Supplementary Fig. 3b), we assessed neoGATA3
function in T47D and ZR75-1, two ER+ /GATA3+BC
Fig. 3 NeoGATA3 is associated with altered ER-dependent tran-
scriptional program. a GSEA on the ranked list of genes differen-
tially regulated in neoGATA3 tumors (n= 65) compared with all other
tumors of the METABRIC ER+ cohort (n= 1345). The “Hallmarks”
collection of gene sets was interrogated. The graphs show the nor-
malized enrichment score (NES) of the ten gene sets most significantly
enriched among the upregulated (red) and the downregulated (blue)
genes. FDR < 0.05 for all gene sets shown. b Gene expression data for
the indicated cell cycle-related genes in the METABRIC ER+ patients
belonging to the three groups (WT n= 1189, neoGATA3 n= 66,
OtherMut n= 155). c RPPA data from the TCGA cohort showing
expression levels of the indicated proteins in the three tumor groups
(WT n= 533, neoGATA3 n= 18, OtherMut n= 75). d Enrichment
plots for genesets defined by Ross-Innes et al. comparing gene
expression in tumors responding to endocrine therapy and tumors with
poor response. GSEA was performed on genes differentially regulated
in the neoGATA3 tumors from the METABRIC ER+ cohort.
e Enrichment plots for two progesterone-related genesets among the
differentially expressed genes in the METABRIC neoGATA3 patients
compared to all other METABRIC ER+. Mann–Whitney U test was
used in (b, c). *P < 0.05, **P < 0.01.
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cell lines (Supplementary Fig. 7a). NeoGATA3 was more
stable also in this context and the stability of endogenous
GATA3 was not affected by the mutant (Fig. 5a, estimated
half-life: >8 h vs 2 h). This is consistent with the observa-
tion that, in the TCGA-BRCA series, total GATA3 protein
levels were significantly higher in the neoGATA3-mutant
vs. WT tumors (P= 1.72e−07) [3] (Fig. 5b). Over-
expression of wtGATA3 or neoGATA3 had no significant
effect on proliferation and wound healing capacity of T47D
and ZR75-1 cells (Supplementary Fig. 7b, c).
The patient-based transcriptomics analyses suggested
that neoGATA3 modulates the ER-dependent program.
Treatment of hormone-depleted control T47D cells with
17β-estradiol (E2) induced proliferation at 24–72 h,
which was blunted by 4OH-Tamoxifen (TMX). By con-
trast, neoGATA3-expressing cells showed a significantly
lower response to E2 (P= 0.025) (Fig. 5c, d). WtGATA3-
overexpressing cells showed an intermediate phenotype
(Fig. 5c, d). Similar, although less prominent, findings
were made using ZR75-1 cells (Supplementary Fig. 8a,
b). This observation was at odds with the enrichment of
the two “Estrogen response” Hallmarks genes sets among
overexpressed genes in the neoGATA3 tumors from
patients. However, the Hallmarks gene sets do not dis-
criminate between up- or down-regulated genes, therefore
we performed GSEA on the METABRIC gene expression
dataset, using an ad-hoc subset of estradiol- and TMX-
related signatures selected from the MSigDb, with sepa-
rate up- and down-regulated genes. The two signatures
“Dutertre_E2_6h_UP” and “Dutertre_E2_24h_UP”, cor-
responding to genes upregulated in MCF7 BC cells upon
E2 stimulation for 6 h or 24 h, respectively, were sig-
nificantly enriched among the genes downregulated in
neoGATA3 tumors, consistent with our in vitro
Fig. 4 Biochemical and functional characteristics of neoGATA3
differ from wtGATA3. a Western blot showing the expression of
wtGATA3 or neoGATA3 upon gene transduction in the GATA3-
negative BT20 cells, after treatment with 50 µg/ml cycloheximide
(CHX) for the indicated time. Vinculin was used as loading control.
Quantification of relative band intensity is shown at the bottom.
Images are representative of at least three independent experiments.
b Immunofluorescence using the N-ter GATA3 antibody (top panels)
or tag-specific antibodies (bottom panels, left: Flag, right: HA) in
BT20 cells expressing either Flag-wtG3 or HA-neoG3, as indicated.
DAPI was used to counterstain nuclei, GFP was expressed by the
lentiviral vector used for the transduction. c EMSA assay performed
with recombinant wtGATA3 or neoGATA3 and DNA fragment con-
taining two GATAA motifs. d Reporter assay using the promoter
regions of either CDH1 or CDH3 upstream of the luciferase cDNA.
HEK293 cells were transiently transfected with the indicated con-
structs and luciferase activity was measured after 48 h. A GFP-
expressing plasmid was co-transfected to normalize for transfection
efficiency by western blotting (not shown). e Growth curve (left) and
percentage of BrdU+ cells (right) measured in BT20 cells transduced
with the indicated constructs. Data are represented as mean ± standard
deviation of at least three independent experiments. Two-sided Stu-
dent’s t test *P < 0.05, **P < 0.01.
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observations (Fig. 5e). These data, together with the
concordance between lower E2-induced proliferation
in vitro and better outcome in patients, support the use of
cell lines in vitro to investigate neoGATA3 function. Of
note, gene expression signatures related to resistance to
TMX in BC cell lines were also regulated in the neo-
GATA3 tumors (Fig. 5e).
Genomic binding of ER is altered in
neoGATA3-expressing cells
To understand how neoGATA3 interferes with the ER-
dependent program, we checked the modulation of the ER
protein upon hormone starvation and subsequent stimula-
tion with E2 or TMX, which induce a reduction and an
increase of ER, respectively [17]. NeoGATA3 expression
did not affect the total ER levels in any of the tested con-
ditions in T47D cells (Supplementary Fig. 8c, d).
No difference was observed in chromatin-bound ER in
hormone-starved T47D cells expressing neoGATA3 com-
pared to Ctrl or wtGATA3-overexpressing cells. However,
after stimulation with 10 nM E2 the drop in chromatin-
bound ER was significantly more pronounced in
neoGATA3-expressing cells compared to both Ctrl (P=
0.036) and wtGATA3-overexpressing cells (P= 0.016)
suggesting that neoGATA3 interferes with the genomic
binding of ER to some of its targets upon estrogen stimu-
lation (Fig. 6a).
We then assessed the genomic localization of ER in Ctrl
or neoGATA3-expressing T47D cells with ChIP-Seq, after
48 h of hormone starvation followed by stimulation with
10 nM E2. When merging replicates (Supplementary Fig.
9a) the total number of ER peaks was slightly reduced in
neoGATA3 cells (7710) compared with Ctrl cells (9096)
and 5591/7710 peaks (72.5%) were overlapping with
peaks detected in Ctrl cells. Visual inspection of a set of
peaks showed reduced signal in neoGATA3-expressing
cells (Fig. 6b and Supplementary Fig. 9b–f). Differential
binding analysis revealed that most of the common peaks
had reduced ER enrichment in neoGATA3-expressing
cells, with 1253 peaks showing significantly reduced
binding, and only one peak with significantly higher
binding (Fig. 6c). This is in accordance with an overall
reduced binding of ER to the chromatin after stimulation
with estrogen (Fig. 6a). Interestingly, 26.9% of all ER
peaks but only 9.9% of those with reduced ER enrichment
Fig. 5 NeoGATA3 interferes with response to estradiol in ER+
cells. a Western blot showing the expression of endogenous GATA3
or ectopically expressed neoGATA3 in T47D cells treated with 50 µg/
ml CHX for the indicated time. Vinculin was used as loading control.
Quantification of relative band intensity is shown at the bottom. The
endogenous GATA3 band was quantified as well in the neoGATA3-
transduced cells. The images are representative of at least three inde-
pendent experiments. b RPPA data from the TCGA cohort showing
GATA3 expression levels in tumors of the three groups of patients
(WT n= 533, neoGATA3 n= 18). c Graphs showing the relative cell
growth of T47D cells transduced with the indicated constructs, after
48 h in hormone-depleted (HD) medium followed by 72 h of treatment
with E2 (10 nM) or with E2 (10 nM) and TMX (1 μM). All values are
normalized to vehicle-treated cells of each experimental group. Data
are represented as mean ± standard deviation of at least three inde-
pendent experiments. Two-sided Student’s t test *P < 0.05 compared
with treated Ctrl cells, #P < 0.05 compared to vehicle-treated cells of
the same experimental group. d Graphs showing the percentage of
BrdU-positive nuclei in T47D cells transduced with the indicated
constructs, after 48 h in HD medium followed by 24 h treatment with
E2 (10 nM) or with vehicle. Data are represented as mean ± standard
deviation of at least three independent experiments. Two-sided Stu-
dent’s t test showed no statistically significant differences. e Enrich-
ment plots for genesets related with estradiol stimulation and
tamoxifen resistance in vivo. GSEA was performed on genes differ-
entially expressed in METABRIC neoGATA3 tumors.
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in neoGATA3-expressing cells were located within 5 kb
from a TSS (Fig. 6d, P < 0.002) suggesting that neo-
GATA3 influences mostly the fine tuning of ER-dependent
transcription, consistent with the subtle differences we
observed in these cells.
To evaluate the extent to which our observations in
T47D cells might reflect the scenario in patients, we
analyzed the ER binding density in Ctrl and neoGATA3-
expressing T47D cells at ChIP-Seq peaks located around
the TSS of genes that were differentially expressed in
neoGATA3 tumors from the METABRIC cohort. The
binding density of ER peaks in neoGATA3-expressing
cells was especially reduced on distal regions, indepen-
dently from the resulting transcriptional effect (Fig. 6e).
Interestingly, the binding density of peaks located at the
TSS of genes that were either unchanged or down-
regulated in neoGATA3 tumors was maintained in
neoGATA3-expressing T47D cells, but lower on the TSS
of genes upregulated in neoGATA3 tumors (Fig. 6e, f).
This suggests that neoGATA3 partially interferes with
ER binding especially at enhancers and at the TSS of ER
target genes that are repressed by ER. Of note, ER
binding intensity in Ctrl T47D cells was generally higher
on genes that were differentially expressed in neo-
GATA3 tumors compared to unchanged genes, sup-
porting the use of this cellular model to understand
neoGATA3 function in the context of ER-dependent
transcription.
Fig. 6 NeoGATA3 reduces the binding of ER to chromatin.
a Western blot showing chromatin-bound ER and GATA3 in T47D
cells transduced with the indicated constructs and treated as indicated
for 24 h after 48 h in HD medium. Ponceau staining was used to assess
equal loading. The quantification of the ER band intensity from three
independent experiments is shown below. b Visualization of ChIP-Seq
results in the genome browser. Magnification of the region in the box
shows reduced ER signal in neoGATA3-expressing cells at the TSS of
NRIP1. c Plot showing the differential binding of ER in Ctrl versus
neoGATA3-expressing T47D cells. In pink are the peaks that show
significantly reduced or increased ER enrichment in neoGATA3 cells
calculated with DiffBind analysis. d Distribution of all peaks and
peaks with reduced ER enrichment in neoGATA3 cells across the
indicated intervals of distance from the TSS of the gene annotated to
the peak. Chi-square test for differences in frequencies was applied.
e ER binding density plot showing the enrichment of ER at ChIP-Seq
peaks in Ctrl (black) and neoGATA3-expressing (orange) T47D cells
considering genes that are upregulated, downregulated, or unchanged
in the METABRIC ER+neoGATA3 tumors. f Box-plots show Log2
fold changes of normalized ER signals in neoGATA3-expressing
T47D cells compared to controls. Signals were analyzed in regions ±
25 bp around TSS of genes that were upregulated (n= 999), down-
regulated (n= 921), or unchanged (n= 11537) in METABRIC neo-
GATA3 tumors. The signals are average values from ChIP-seq
experiments in three biological replicates. Kruskal–Wallis P < 0.0001.
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NeoGATA3 interferes with progesterone-induced
growth arrest
While the essential role of GATA3 for ER activity is well
known, its relation with PR is much less studied. Neo-
GATA3 appeared to interfere with the transcriptional
response to progesterone in tumors, especially in pre-
menopause (Fig. 3e and Supplementary Fig. 5a). We there-
fore investigated the role of neoGATA3 in the PR-dependent
program. As reported [6], hyperstimulation with P4 induced
growth arrest in T47D cells, measured as BrdU incorporation
after 24 h (Fig. 7a) and as cell viability after 6 days (Fig. 7b).
This growth arrest was significantly reduced in neoGATA3-
expressing cells both at 24 h (P= 0.041) and after 6 days
(P= 0.007). When the P4-arrested cells were changed back
to normal medium, with lower progesterone levels, for 3
additional days, both control and wtGATA3-overexpressing
cells partially recovered proliferation, while neoGATA3-
expressing cells remained arrested (Fig. 7b).
Interestingly, both GATA3 and neoGATA3 (in
neoGATA3-expressing cells) were strikingly more abun-
dant in the PR complex than in the ER complex, as shown
by co-immunoprecipitation (Supplementary Fig. 10). Con-
sistent with the lack of S308 in the neoGATA3, its
expression was not reduced after treatment with 100 nM
progesterone (P4) for 24 h, as opposed to endogenous
GATA3 both in Ctrl and in neoGATA3-expressing cells
(Fig. 7c). Interestingly, exogenous wtGATA3 was not
reduced upon P4 treatment, possibly due to the over-
expression of the protein from an ectopic promoter, evading
the PR-dependent transcriptional inhibition [26].
Discussion
GATA3 is a paradigm of how genetic alterations in a given
gene should not be lumped into a single class [5, 6]. Our
work adds an important concept, namely that a single
mutation might have distinct functions, depending on the
context of the disease. This calls for an exhaustive func-
tional characterization to refine our understanding of driver
mutations roles and improve clinical application.
The GATA3 X308_Splice mutation is predicted to
produce a mutant protein lacking the second ZnFn and
carrying a unique 44aa peptide (neoGATA3). Importantly,
we identified five additional mutations predicted to gen-
erate a protein with partially or fully identical C-terminal
peptides, supporting a selective pressure toward con-
vergent oncogenic evolution. Here we provide formal
proof, using a novel peptide-specific antibody, that neo-
GATA3 mutations are associated with less aggressive
tumors and better outcome in patients. In vitro, neo-
GATA3 interferes with ER genomic binding upon
estrogen stimulation, especially at enhancer regions. In
addition, neoGATA3 interferes with the PR-dependent
antiproliferative program in a progesterone-high context.
To understand the molecular function of neoGATA3
mutations in BC, we turned to an in vitro model. Neo-
GATA3 mutations are typically heterozygous, and the
wtGATA3 protein is still expressed. Unfortunately, we did
not manage to find or generate any cellular model carrying
the mutation in the endogenous locus, therefore we decided
to use lentiviral transduction of ER+ cell lines. To control
for increased abundance of total GATA3 proteins, we
included wtGATA3-transduced cells. Indeed, the latter
often showed an intermediate phenotype between Ctrl and
neoGATA3-expressing cells, highlighting the limitations of
our model. This might also suggest that part of the
neoGATA3-dependent effects are simply due to its higher
stability. Importantly, the major findings from our in vitro
experiments were consistent with patient-based observa-
tions and we believe that our in vitro system is informative
despite its limitations. Given the prevalence of neoGATA3
mutations in patients, the lack of models carrying them
endogenously is striking and suggests that these alterations
are likely weak drivers, conferring mild proliferative
advantage only in specific contexts that are not easily
reproduced ex vivo or in vitro.
The unique C-terminal peptide of neoGATA3 is a pre-
dicted neoantigen [21] proposed to be associated with
increased T-cell-mediated immune response [29]. A
neoantigen-elicited tumor clearance by the immune system
would be an appealing explanation for the better outcome
observed in patients carrying neoGATA3 mutations. How-
ever, we did not find evidence for this using multiple
methods of analysis. The tumor immune milieu is indeed
altered in neoGATA3 tumors, but the exact contribution of
the immune infiltrates to their phenotype and whether/how
neoGATA3 directly or indirectly influences the tumor
microenvironment remains to be understood.
Our analyses of patient-derived datasets highlighted the
ER-dependent transcriptome as highly altered in neo-
GATA3 tumors, in line with the known function of GATA3
as a crucial ER co-factor [11]. Indeed neoGATA3 expres-
sion reduced, but did not fully abrogate, the response to
estrogen in two ER+ BC cell lines. In particular, we
observed a significant reduction of the chromatin-bound
ER. In addition, ChIP-Seq revealed that the loss of ER
binding was especially pronounced on regions far from the
TSS, possibly enhancers. This suggests that neoGATA3
interferes mainly with the fine-tuning of ER-dependent
transcription, consistent with the rather mild biological
effects observed. As the C-terminal part of GATA3 is
thought to modulate protein–protein interactions, the novel
peptide contained in neoGATA3 could quench the forma-
tion of a functional DNA-binding ER complex or alter
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co-factors accessibility. Our analyses suggest that there
might be a more obvious modulation of genes that are
normally repressed by ER.
Having provided hints on the possible mechanism link-
ing neoGATA3 to better prognosis in patients, we were
puzzled by the fact that the neoGATA3 mutations, unfa-
vorable for tumor cells, are highly selected during tumor
evolution. We reasoned that there might be a context in
which neoGATA3 grants a proliferative advantage. Neo-
GATA3 mutations are remarkably frequent among pre-
menopausal patients, where estrogens and progestogens
levels are relatively high and ER and PR have antagonistic
effects through the modulation of shared targets [30].
GATA3 and PR are in the same protein complex [31]
and PR reduces GATA3 both at transcriptional and
post-translational levels, in particular by inducing
Fig. 7 NeoGATA3 interferes with the PR-dependent growth
arrest. a Graph showing the relative percentage of BrdU+ cells in the
indicated cell population after 24 h treatment with vehicle or 100 nM
P4. b Graph showing the relative cell viability measured with crystal
violet staining of the indicated cell populations after vehicle-treatment,
6 days treatment with 100 nM P4, or 3 days with 100 nM P4 followed
by additional 3 days in normal medium. Cells were kept in normal
medium containing hormones. In a, b the results are normalized to the
respective vehicle control and are shown as mean ± standard deviation
of at least three independent experiments. Two-sided Student’s t test
*P < 0.05. c Western blot showing expression of PR, wtGATA3, and
neoGATA3 in T47D cells transduced with the indicated constructs and
treated with progesterone (P4) (100 nM) for 24 h in normal medium.
GAPDH was used as loading control. d The working model: neo-
GATA3 is a weak oncogenic driver with highly context-dependent
functions. In a progesterone-rich environment, it interferes with the
antiproliferative PR-driven program, whereas in an estrogen-rich
context it blunts the pro-mitogenic ER-dependent response. Proges-
terone drops faster than estrogen at menopause, therefore it is possible
that neoGATA3 mutations are enriched in premenopause patients
because of this context-dependent opposite effects.
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phosphorylation of S308, which prompts GATA3 ubiqui-
tination [26]. The strong selection of mutations abrogating
this residue points toward a function in evading the PR-
dependent antiproliferative program as we observed in
T47D, where progesterone-induced growth arrest was less
prominent in neoGATA3-expressing cells. Interestingly,
wtGATA3 expression in T47D cells from an ectopic pro-
moter evading PR-dependent transcriptional inhibition
showed a tendency to reduce progesterone-induced growth
arrest and 4 of the 5 neoGATA3-like mutations retain the
S308 residue and are therefore likely degraded in response
to progesterone. This would indicate that the increased
stability of neoGATA3 is not the only explanation for the
interference with PR function. Our data suggest that
GATA3 is a crucial co-factor for both ER and PR and
further—omics studies should be performed to assess its
precise role in their transcriptional programs.
Intriguingly, the wtGATA3 was expressed at lower
levels than neoGATA3 in T47D cells, yet wtGATA3-
transduced cells often showed intermediate phenotypes
between Ctrl-transduced and neoGATA3-expressing cells.
This would suggest that an increase in GATA3 expression
is sufficient to disrupt the balance between ER and PR
programs, and that neoGATA3 is less efficient than the WT
protein at doing this. Therefore, neoGATA3 behaves as a
weak, inefficient, oncogenic driver.
In conclusion, our data suggest that neoGATA3
mutations are specifically selected in a molecular context
where estrogen-driven mitogenic phenotypes are coun-
terbalanced by progesterone-driven antiproliferative
effects. In this scenario, the net output of neoGATA3
interference with both ER and PR programs seems to be a
proliferative advantage. On the other hand, in a context
where the ER-dependent program dominates, neoGATA3
confers a proliferative disadvantage and is associated with
better patient outcome (Fig. 7d). The neoGATA3 muta-
tions therefore represent a subtype of context-dependent
weak driver mutations associated with distinct clinical
features.
Methods
Patient samples and patient-related information
FFPE sections, DNA, RNA, and protein lysates from BC
samples were obtained from the CRUK Cambridge, the
Hospital INCLIVA (Valencia), and the Hospital Vall
d’Hebron (Barcelona). Transciptomic data from TCGA and
METABRIC were downloaded from cbioportal.org. All
procedures were approved by the institutional Ethics
Committees and informed consent was obtained from all
patients.
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